Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes
Monday, August 31, 2009 - 09:28
in Health & Medicine
Barcelona, Spain, August 30: Data from a phase II trial of an investigational intravenous drug designed to block the formation of blood clots shows potential to reduce the risk of death, a second heart attack, or other coronary complications compared with the current standard of care in patients presenting with acute coronary syndromes (heart attacks or unstable angina).